Alan Skarbnik, MD

home / authors / alan-skarbnik-md

Alan Skarbnik, MD, serves as the director of the lymphoma and chronic lymphocytic leukemia program and director of experimental therapeutics, malignant hematology at Novant Health.

Articles

Follicular Lymphoma: Emerging Treatments

Alan Skarbnik, MD

October 11th 2021

An oncologist ruminates on emerging treatment options in follicular lymphoma and offers some clinical pearls.

Treating Early Relapse in Follicular Lymphoma

Alan Skarbnik, MD

October 11th 2021

Alan Skarbnik, MD, explains early relapse in follicular lymphoma and the available treatment options.

Monitoring Strategies in Follicular Lymphoma

Alan Skarbnik, MD

October 11th 2021

An expert describes typical monitoring strategies in follicular lymphoma.

Follicular Lymphoma: The GALLIUM Study

Alan Skarbnik, MD

October 11th 2021

Dr. Alan Skarbnik reviews the use of obinutuzumab-based therapies for follicular lymphoma and highlights data from a phase III study.

Induction Therapy Options in Follicular Lymphoma

Alan Skarbnik, MD

October 11th 2021

A key opinion leader discusses the considerations in choosing induction and maintenance therapy options for follicular lymphoma.

Case Overview: A 60-Year-Old Man with Newly Diagnosed Follicular Lymphoma

Alan Skarbnik, MD

October 11th 2021

Alan Skarbnik, MD, presents the case of a 60-year-old man with newly diagnosed follicular lymphoma.

Challenges With Triplet Regimens for the Treatment of Hematologic Malignancies

Alan Skarbnik, MD

April 18th 2018

Alan Skarbnik, MD, director of the Chronic Lymphocytic Leukemia Program at John Theurer Cancer Center, discusses the possibility of triplet combinations for the treatment of hematologic malignances. The biggest challenge with this type of treatment regimen is the increased risk of adverse events.